United-Guardian Q1 Sales Rise to $2.87 Million, Net Income Up to $818,902
United-Guardian reported first quarter 2026 net sales of $2,872,222, up from $2,481,127 a year earlier, and net income of $818,902 ($0.18 per share), up from $560,895 ($0.12 per share). The company said the gain was driven by higher pharmaceutical and cosmetic ingredient sales, and also included $303,133 of settlement income from its contract manufacturer of Renacidin.
Key points
- Net sales rose to $2,872,222 in Q1 2026 from $2,481,127 in Q1 2025.
- Net income rose to $818,902 ($0.18 per share) from $560,895 ($0.12 per share).
- Settlement income of $303,133 from the Renacidin contract manufacturer contributed to the quarter's results; income from operations was $642,449 versus $610,922.
- Management said Ashland Specialty Ingredients' purchases rose 45% year over year after it worked through excess inventory.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.